Status:
COMPLETED
The Protrieve PROTECTOR Study
Lead Sponsor:
Inari Medical
Conditions:
Venous Thromboembolism
Deep Venous Thrombosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Detailed Description
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
- Bilateral iliofemoral DVT
- Clot extending into or located in the IVC
- In-stent thrombosis
- Presence of thrombosed IVC filter
- Other features that the investigator deems put the subject at elevated risk for thromboembolism
- Willing and able to provide informed consent
Exclusion
- Current symptomatic PE
- Known anatomic inability to place Protrieve device via jugular vein access site
- Presence of clot extending to the IVC-Right Atrial junction or in the SVC
- Subject is pregnant
- Severe allergy to iodinated contrast agents that cannot be mitigated
- INR \> 1.7 if not currently on anticoagulation therapy, platelets \< 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin \< 8.0 g/dL
- Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
- Subject is participating in another study that may interfere with this study
- Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Subject has previously completed or withdrawn from this study
- Limb-threatening circulatory compromise (e.g., phlegmasia)
- Uncontrolled severe hypertension on repeated readings (systolic \> 180mmHg or diastolic \> 105mmHg)
- Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
- Inability to provide therapeutic anticoagulation per Investigator discretion
- Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Key Trial Info
Start Date :
March 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 6 2025
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT06495996
Start Date
March 5 2025
End Date
November 6 2025
Last Update
December 3 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Hoag Hospital
Newport Beach, California, United States, 92663
2
Yale University
New Haven, Connecticut, United States, 06510
3
Baptist Health South Florida
Miami, Florida, United States, 33176
4
IU Health Methodist Hospital
Indianapolis, Indiana, United States, 46204